- Home
- PCRX vs USNA Comparison
PCRX vs USNA Comparison
Compare PCRX & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- USNA
- Stock Information
- Founded
- PCRX 2006
- USNA 1992
- Country
- PCRX United States
- USNA United States
- Employees
- PCRX N/A
- USNA N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- USNA Medicinal Chemicals and Botanical Products
- Sector
- PCRX Health Care
- USNA Health Care
- Exchange
- PCRX Nasdaq
- USNA Nasdaq
- Market Cap
- PCRX 1.2B
- USNA 565.2M
- IPO Year
- PCRX 2011
- USNA 1996
- Fundamental
- Price
- PCRX $22.73
- USNA $31.33
- Analyst Decision
- PCRX Buy
- USNA Hold
- Analyst Count
- PCRX 8
- USNA 1
- Target Price
- PCRX $28.38
- USNA $36.00
- AVG Volume (30 Days)
- PCRX 492.0K
- USNA 149.1K
- Earning Date
- PCRX 07-29-2025
- USNA 07-22-2025
- Dividend Yield
- PCRX N/A
- USNA N/A
- EPS Growth
- PCRX N/A
- USNA N/A
- EPS
- PCRX N/A
- USNA 1.82
- Revenue
- PCRX $702,772,000.00
- USNA $876,242,000.00
- Revenue This Year
- PCRX $7.92
- USNA $13.04
- Revenue Next Year
- PCRX $11.02
- USNA $7.36
- P/E Ratio
- PCRX N/A
- USNA $17.94
- Revenue Growth
- PCRX 3.08
- USNA N/A
- 52 Week Low
- PCRX $11.16
- USNA $23.10
- 52 Week High
- PCRX $27.64
- USNA $48.85
- Technical
- Relative Strength Index (RSI)
- PCRX 36.58
- USNA 49.84
- Support Level
- PCRX $22.23
- USNA $32.01
- Resistance Level
- PCRX $23.91
- USNA $33.95
- Average True Range (ATR)
- PCRX 0.82
- USNA 0.91
- MACD
- PCRX -0.01
- USNA -0.03
- Stochastic Oscillator
- PCRX 22.03
- USNA 27.49
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About USNA USANA Health Sciences Inc.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.